nodes	percent_of_prediction	percent_of_DWPC	metapath
Sumatriptan—ABCB1—peripheral nervous system neoplasm	0.273	1	CbGaD
Sumatriptan—ABCG2—Topotecan—peripheral nervous system neoplasm	0.0793	0.214	CbGbCtD
Sumatriptan—ABCG2—Dactinomycin—peripheral nervous system neoplasm	0.055	0.148	CbGbCtD
Sumatriptan—ABCG2—Vincristine—peripheral nervous system neoplasm	0.0339	0.0912	CbGbCtD
Sumatriptan—ABCG2—Cisplatin—peripheral nervous system neoplasm	0.0316	0.085	CbGbCtD
Sumatriptan—ABCG2—Etoposide—peripheral nervous system neoplasm	0.031	0.0835	CbGbCtD
Sumatriptan—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0286	0.077	CbGbCtD
Sumatriptan—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0286	0.077	CbGbCtD
Sumatriptan—ABCG2—Doxorubicin—peripheral nervous system neoplasm	0.0212	0.057	CbGbCtD
Sumatriptan—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0198	0.0534	CbGbCtD
Sumatriptan—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0122	0.0329	CbGbCtD
Sumatriptan—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0114	0.0307	CbGbCtD
Sumatriptan—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0112	0.0301	CbGbCtD
Sumatriptan—HTR1D—meninx—peripheral nervous system neoplasm	0.0112	0.117	CbGeAlD
Sumatriptan—HTR1F—trigeminal nerve—peripheral nervous system neoplasm	0.0111	0.117	CbGeAlD
Sumatriptan—HTR1B—dura mater—peripheral nervous system neoplasm	0.0106	0.111	CbGeAlD
Sumatriptan—HTR1D—dura mater—peripheral nervous system neoplasm	0.0103	0.108	CbGeAlD
Sumatriptan—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.00763	0.0205	CbGbCtD
Sumatriptan—HTR3A—vagus nerve—peripheral nervous system neoplasm	0.00508	0.0534	CbGeAlD
Sumatriptan—HTR1B—trigeminal nerve—peripheral nervous system neoplasm	0.00456	0.0479	CbGeAlD
Sumatriptan—HTR1D—trigeminal nerve—peripheral nervous system neoplasm	0.00442	0.0464	CbGeAlD
Sumatriptan—HTR1F—ganglion—peripheral nervous system neoplasm	0.00401	0.0422	CbGeAlD
Sumatriptan—HTR3A—cranial nerve—peripheral nervous system neoplasm	0.00387	0.0407	CbGeAlD
Sumatriptan—HTR1B—cranial nerve—peripheral nervous system neoplasm	0.00325	0.0341	CbGeAlD
Sumatriptan—HTR1D—cranial nerve—peripheral nervous system neoplasm	0.00315	0.0331	CbGeAlD
Sumatriptan—HTR3A—nerve—peripheral nervous system neoplasm	0.00199	0.0209	CbGeAlD
Sumatriptan—HTR3A—ganglion—peripheral nervous system neoplasm	0.00196	0.0206	CbGeAlD
Sumatriptan—HTR1B—ganglion—peripheral nervous system neoplasm	0.00164	0.0173	CbGeAlD
Sumatriptan—HTR1D—ganglion—peripheral nervous system neoplasm	0.00159	0.0167	CbGeAlD
Sumatriptan—HTR1A—ganglion—peripheral nervous system neoplasm	0.00133	0.0139	CbGeAlD
Sumatriptan—MAOA—nerve—peripheral nervous system neoplasm	0.00123	0.0129	CbGeAlD
Sumatriptan—DRD2—nerve—peripheral nervous system neoplasm	0.00121	0.0128	CbGeAlD
Sumatriptan—MAOA—ganglion—peripheral nervous system neoplasm	0.00121	0.0127	CbGeAlD
Sumatriptan—DRD2—ganglion—peripheral nervous system neoplasm	0.0012	0.0126	CbGeAlD
Sumatriptan—HTR3A—trigeminal ganglion—peripheral nervous system neoplasm	0.000963	0.0101	CbGeAlD
Sumatriptan—HTR3A—brainstem—peripheral nervous system neoplasm	0.000852	0.00895	CbGeAlD
Sumatriptan—HTR1B—trigeminal ganglion—peripheral nervous system neoplasm	0.000808	0.00849	CbGeAlD
Sumatriptan—HTR1D—trigeminal ganglion—peripheral nervous system neoplasm	0.000782	0.00822	CbGeAlD
Sumatriptan—HTR1B—brainstem—peripheral nervous system neoplasm	0.000715	0.00751	CbGeAlD
Sumatriptan—HTR1D—brainstem—peripheral nervous system neoplasm	0.000692	0.00727	CbGeAlD
Sumatriptan—MAOA—trigeminal ganglion—peripheral nervous system neoplasm	0.000596	0.00626	CbGeAlD
Sumatriptan—HTR1A—brainstem—peripheral nervous system neoplasm	0.000577	0.00606	CbGeAlD
Sumatriptan—MAOA—parotid gland—peripheral nervous system neoplasm	0.000562	0.0059	CbGeAlD
Sumatriptan—MAOA—brainstem—peripheral nervous system neoplasm	0.000527	0.00554	CbGeAlD
Sumatriptan—DRD2—brainstem—peripheral nervous system neoplasm	0.000521	0.00548	CbGeAlD
Sumatriptan—ABCG2—trigeminal ganglion—peripheral nervous system neoplasm	0.000516	0.00542	CbGeAlD
Sumatriptan—ABCG2—parotid gland—peripheral nervous system neoplasm	0.000487	0.00512	CbGeAlD
Sumatriptan—SLCO1A2—cerebellum—peripheral nervous system neoplasm	0.000332	0.00348	CbGeAlD
Sumatriptan—HTR1A—cerebellum—peripheral nervous system neoplasm	0.000284	0.00299	CbGeAlD
Sumatriptan—MAOA—cerebellum—peripheral nervous system neoplasm	0.00026	0.00273	CbGeAlD
Sumatriptan—DRD2—cerebellum—peripheral nervous system neoplasm	0.000257	0.0027	CbGeAlD
Sumatriptan—ABCB1—trigeminal ganglion—peripheral nervous system neoplasm	0.000255	0.00267	CbGeAlD
Sumatriptan—ABCG2—cerebellum—peripheral nervous system neoplasm	0.000225	0.00237	CbGeAlD
Sumatriptan—ABCB1—cerebellum—peripheral nervous system neoplasm	0.000111	0.00117	CbGeAlD
Sumatriptan—Influenza—Epirubicin—peripheral nervous system neoplasm	6.86e-05	0.000287	CcSEcCtD
Sumatriptan—Dysphagia—Epirubicin—peripheral nervous system neoplasm	6.86e-05	0.000287	CcSEcCtD
Sumatriptan—Dehydration—Doxorubicin—peripheral nervous system neoplasm	6.83e-05	0.000286	CcSEcCtD
Sumatriptan—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	6.82e-05	0.000285	CcSEcCtD
Sumatriptan—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	6.81e-05	0.000285	CcSEcCtD
Sumatriptan—Tachycardia—Etoposide—peripheral nervous system neoplasm	6.79e-05	0.000284	CcSEcCtD
Sumatriptan—Abdominal pain—Vincristine—peripheral nervous system neoplasm	6.79e-05	0.000284	CcSEcCtD
Sumatriptan—Body temperature increased—Vincristine—peripheral nervous system neoplasm	6.79e-05	0.000284	CcSEcCtD
Sumatriptan—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	6.78e-05	0.000283	CcSEcCtD
Sumatriptan—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	6.77e-05	0.000283	CcSEcCtD
Sumatriptan—Skin disorder—Etoposide—peripheral nervous system neoplasm	6.76e-05	0.000283	CcSEcCtD
Sumatriptan—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	6.72e-05	0.000281	CcSEcCtD
Sumatriptan—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	6.72e-05	0.000281	CcSEcCtD
Sumatriptan—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	6.68e-05	0.000279	CcSEcCtD
Sumatriptan—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	6.6e-05	0.000276	CcSEcCtD
Sumatriptan—Bronchitis—Epirubicin—peripheral nervous system neoplasm	6.59e-05	0.000276	CcSEcCtD
Sumatriptan—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	6.58e-05	0.000275	CcSEcCtD
Sumatriptan—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	6.56e-05	0.000275	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	6.55e-05	0.000274	CcSEcCtD
Sumatriptan—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	6.51e-05	0.000272	CcSEcCtD
Sumatriptan—Hypotension—Etoposide—peripheral nervous system neoplasm	6.5e-05	0.000272	CcSEcCtD
Sumatriptan—Gastritis—Doxorubicin—peripheral nervous system neoplasm	6.5e-05	0.000272	CcSEcCtD
Sumatriptan—Pain—Cisplatin—peripheral nervous system neoplasm	6.49e-05	0.000272	CcSEcCtD
Sumatriptan—Dysuria—Epirubicin—peripheral nervous system neoplasm	6.41e-05	0.000268	CcSEcCtD
Sumatriptan—Asthenia—Alitretinoin—peripheral nervous system neoplasm	6.39e-05	0.000267	CcSEcCtD
Sumatriptan—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	6.39e-05	0.000267	CcSEcCtD
Sumatriptan—Asthma—Doxorubicin—peripheral nervous system neoplasm	6.34e-05	0.000265	CcSEcCtD
Sumatriptan—Influenza—Doxorubicin—peripheral nervous system neoplasm	6.34e-05	0.000265	CcSEcCtD
Sumatriptan—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	6.34e-05	0.000265	CcSEcCtD
Sumatriptan—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	6.33e-05	0.000265	CcSEcCtD
Sumatriptan—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	6.33e-05	0.000265	CcSEcCtD
Sumatriptan—Pruritus—Alitretinoin—peripheral nervous system neoplasm	6.3e-05	0.000264	CcSEcCtD
Sumatriptan—Photosensitivity reaction—Epirubicin—peripheral nervous system neoplasm	6.26e-05	0.000262	CcSEcCtD
Sumatriptan—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	6.26e-05	0.000262	CcSEcCtD
Sumatriptan—Paraesthesia—Etoposide—peripheral nervous system neoplasm	6.25e-05	0.000261	CcSEcCtD
Sumatriptan—Weight increased—Epirubicin—peripheral nervous system neoplasm	6.24e-05	0.000261	CcSEcCtD
Sumatriptan—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	6.22e-05	0.00026	CcSEcCtD
Sumatriptan—Weight decreased—Epirubicin—peripheral nervous system neoplasm	6.2e-05	0.000259	CcSEcCtD
Sumatriptan—Dyspnoea—Etoposide—peripheral nervous system neoplasm	6.2e-05	0.000259	CcSEcCtD
Sumatriptan—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	6.18e-05	0.000259	CcSEcCtD
Sumatriptan—Somnolence—Etoposide—peripheral nervous system neoplasm	6.18e-05	0.000259	CcSEcCtD
Sumatriptan—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	6.18e-05	0.000258	CcSEcCtD
Sumatriptan—Asthenia—Vincristine—peripheral nervous system neoplasm	6.16e-05	0.000258	CcSEcCtD
Sumatriptan—Drowsiness—Epirubicin—peripheral nervous system neoplasm	6.11e-05	0.000256	CcSEcCtD
Sumatriptan—Vomiting—Dactinomycin—peripheral nervous system neoplasm	6.11e-05	0.000256	CcSEcCtD
Sumatriptan—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	6.1e-05	0.000255	CcSEcCtD
Sumatriptan—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	6.1e-05	0.000255	CcSEcCtD
Sumatriptan—Rash—Dactinomycin—peripheral nervous system neoplasm	6.06e-05	0.000253	CcSEcCtD
Sumatriptan—Decreased appetite—Etoposide—peripheral nervous system neoplasm	6.05e-05	0.000253	CcSEcCtD
Sumatriptan—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000252	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	6e-05	0.000251	CcSEcCtD
Sumatriptan—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	6e-05	0.000251	CcSEcCtD
Sumatriptan—Fatigue—Etoposide—peripheral nervous system neoplasm	6e-05	0.000251	CcSEcCtD
Sumatriptan—Constipation—Etoposide—peripheral nervous system neoplasm	5.95e-05	0.000249	CcSEcCtD
Sumatriptan—Pain—Etoposide—peripheral nervous system neoplasm	5.95e-05	0.000249	CcSEcCtD
Sumatriptan—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	5.94e-05	0.000249	CcSEcCtD
Sumatriptan—Dysuria—Doxorubicin—peripheral nervous system neoplasm	5.93e-05	0.000248	CcSEcCtD
Sumatriptan—Dizziness—Alitretinoin—peripheral nervous system neoplasm	5.89e-05	0.000246	CcSEcCtD
Sumatriptan—Diarrhoea—Vincristine—peripheral nervous system neoplasm	5.87e-05	0.000246	CcSEcCtD
Sumatriptan—Sweating—Epirubicin—peripheral nervous system neoplasm	5.86e-05	0.000245	CcSEcCtD
Sumatriptan—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	5.86e-05	0.000245	CcSEcCtD
Sumatriptan—Haematuria—Epirubicin—peripheral nervous system neoplasm	5.83e-05	0.000244	CcSEcCtD
Sumatriptan—Photosensitivity reaction—Doxorubicin—peripheral nervous system neoplasm	5.79e-05	0.000242	CcSEcCtD
Sumatriptan—Weight increased—Doxorubicin—peripheral nervous system neoplasm	5.77e-05	0.000241	CcSEcCtD
Sumatriptan—Epistaxis—Epirubicin—peripheral nervous system neoplasm	5.77e-05	0.000241	CcSEcCtD
Sumatriptan—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.00024	CcSEcCtD
Sumatriptan—Sinusitis—Epirubicin—peripheral nervous system neoplasm	5.74e-05	0.00024	CcSEcCtD
Sumatriptan—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	5.73e-05	0.00024	CcSEcCtD
Sumatriptan—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	5.72e-05	0.000239	CcSEcCtD
Sumatriptan—Nausea—Dactinomycin—peripheral nervous system neoplasm	5.71e-05	0.000239	CcSEcCtD
Sumatriptan—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	5.69e-05	0.000238	CcSEcCtD
Sumatriptan—Dizziness—Vincristine—peripheral nervous system neoplasm	5.68e-05	0.000237	CcSEcCtD
Sumatriptan—Vomiting—Alitretinoin—peripheral nervous system neoplasm	5.67e-05	0.000237	CcSEcCtD
Sumatriptan—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	5.66e-05	0.000237	CcSEcCtD
Sumatriptan—Rash—Alitretinoin—peripheral nervous system neoplasm	5.62e-05	0.000235	CcSEcCtD
Sumatriptan—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	5.61e-05	0.000235	CcSEcCtD
Sumatriptan—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	5.59e-05	0.000234	CcSEcCtD
Sumatriptan—Bradycardia—Epirubicin—peripheral nervous system neoplasm	5.59e-05	0.000234	CcSEcCtD
Sumatriptan—Headache—Alitretinoin—peripheral nervous system neoplasm	5.58e-05	0.000233	CcSEcCtD
Sumatriptan—Urticaria—Etoposide—peripheral nervous system neoplasm	5.53e-05	0.000231	CcSEcCtD
Sumatriptan—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	5.52e-05	0.000231	CcSEcCtD
Sumatriptan—Body temperature increased—Etoposide—peripheral nervous system neoplasm	5.5e-05	0.00023	CcSEcCtD
Sumatriptan—Abdominal pain—Etoposide—peripheral nervous system neoplasm	5.5e-05	0.00023	CcSEcCtD
Sumatriptan—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	5.5e-05	0.00023	CcSEcCtD
Sumatriptan—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	5.49e-05	0.00023	CcSEcCtD
Sumatriptan—Hypoaesthesia—Epirubicin—peripheral nervous system neoplasm	5.46e-05	0.000228	CcSEcCtD
Sumatriptan—Vomiting—Vincristine—peripheral nervous system neoplasm	5.46e-05	0.000228	CcSEcCtD
Sumatriptan—Asthenia—Cisplatin—peripheral nervous system neoplasm	5.45e-05	0.000228	CcSEcCtD
Sumatriptan—Sweating—Doxorubicin—peripheral nervous system neoplasm	5.42e-05	0.000227	CcSEcCtD
Sumatriptan—Rash—Vincristine—peripheral nervous system neoplasm	5.41e-05	0.000226	CcSEcCtD
Sumatriptan—Dermatitis—Vincristine—peripheral nervous system neoplasm	5.41e-05	0.000226	CcSEcCtD
Sumatriptan—ABCG2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	5.4e-05	0.00251	CbGpPWpGaD
Sumatriptan—Haematuria—Doxorubicin—peripheral nervous system neoplasm	5.39e-05	0.000226	CcSEcCtD
Sumatriptan—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	5.39e-05	0.000226	CcSEcCtD
Sumatriptan—Headache—Vincristine—peripheral nervous system neoplasm	5.38e-05	0.000225	CcSEcCtD
Sumatriptan—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	5.34e-05	0.000223	CcSEcCtD
Sumatriptan—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	5.31e-05	0.000222	CcSEcCtD
Sumatriptan—Nausea—Alitretinoin—peripheral nervous system neoplasm	5.29e-05	0.000221	CcSEcCtD
Sumatriptan—DRD2—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	5.29e-05	0.00246	CbGpPWpGaD
Sumatriptan—Visual impairment—Epirubicin—peripheral nervous system neoplasm	5.29e-05	0.000221	CcSEcCtD
Sumatriptan—HTR3A—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	5.26e-05	0.00244	CbGpPWpGaD
Sumatriptan—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	5.19e-05	0.000217	CcSEcCtD
Sumatriptan—HTR1D—Signaling by GPCR—NTS—peripheral nervous system neoplasm	5.17e-05	0.0024	CbGpPWpGaD
Sumatriptan—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	5.17e-05	0.000216	CcSEcCtD
Sumatriptan—HTR3A—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	5.16e-05	0.0024	CbGpPWpGaD
Sumatriptan—Eye disorder—Epirubicin—peripheral nervous system neoplasm	5.13e-05	0.000215	CcSEcCtD
Sumatriptan—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	5.12e-05	0.000214	CcSEcCtD
Sumatriptan—Tinnitus—Epirubicin—peripheral nervous system neoplasm	5.12e-05	0.000214	CcSEcCtD
Sumatriptan—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	5.1e-05	0.000213	CcSEcCtD
Sumatriptan—Nausea—Vincristine—peripheral nervous system neoplasm	5.1e-05	0.000213	CcSEcCtD
Sumatriptan—Flushing—Epirubicin—peripheral nervous system neoplasm	5.09e-05	0.000213	CcSEcCtD
Sumatriptan—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	5.08e-05	0.000212	CcSEcCtD
Sumatriptan—HTR1B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	5.06e-05	0.00235	CbGpPWpGaD
Sumatriptan—Hypoaesthesia—Doxorubicin—peripheral nervous system neoplasm	5.05e-05	0.000211	CcSEcCtD
Sumatriptan—Asthenia—Etoposide—peripheral nervous system neoplasm	4.99e-05	0.000209	CcSEcCtD
Sumatriptan—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	4.99e-05	0.000209	CcSEcCtD
Sumatriptan—Angiopathy—Epirubicin—peripheral nervous system neoplasm	4.98e-05	0.000208	CcSEcCtD
Sumatriptan—HTR1D—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.96e-05	0.0023	CbGpPWpGaD
Sumatriptan—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	4.96e-05	0.000207	CcSEcCtD
Sumatriptan—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	4.95e-05	0.000207	CcSEcCtD
Sumatriptan—Chills—Epirubicin—peripheral nervous system neoplasm	4.92e-05	0.000206	CcSEcCtD
Sumatriptan—Pruritus—Etoposide—peripheral nervous system neoplasm	4.92e-05	0.000206	CcSEcCtD
Sumatriptan—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	4.9e-05	0.000205	CcSEcCtD
Sumatriptan—DRD2—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	4.9e-05	0.00227	CbGpPWpGaD
Sumatriptan—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	4.89e-05	0.000205	CcSEcCtD
Sumatriptan—HTR1A—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	4.88e-05	0.00227	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	4.85e-05	0.00225	CbGpPWpGaD
Sumatriptan—Vomiting—Cisplatin—peripheral nervous system neoplasm	4.83e-05	0.000202	CcSEcCtD
Sumatriptan—Rash—Cisplatin—peripheral nervous system neoplasm	4.79e-05	0.0002	CcSEcCtD
Sumatriptan—SLCO1A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.79e-05	0.00222	CbGpPWpGaD
Sumatriptan—Dermatitis—Cisplatin—peripheral nervous system neoplasm	4.78e-05	0.0002	CcSEcCtD
Sumatriptan—Erythema—Epirubicin—peripheral nervous system neoplasm	4.78e-05	0.0002	CcSEcCtD
Sumatriptan—HTR1F—Signaling Pathways—NTS—peripheral nervous system neoplasm	4.78e-05	0.00222	CbGpPWpGaD
Sumatriptan—Diarrhoea—Etoposide—peripheral nervous system neoplasm	4.76e-05	0.000199	CcSEcCtD
Sumatriptan—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	4.75e-05	0.000198	CcSEcCtD
Sumatriptan—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	4.73e-05	0.000198	CcSEcCtD
Sumatriptan—Flushing—Doxorubicin—peripheral nervous system neoplasm	4.71e-05	0.000197	CcSEcCtD
Sumatriptan—Flatulence—Epirubicin—peripheral nervous system neoplasm	4.71e-05	0.000197	CcSEcCtD
Sumatriptan—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	4.68e-05	0.000196	CcSEcCtD
Sumatriptan—Back pain—Epirubicin—peripheral nervous system neoplasm	4.62e-05	0.000193	CcSEcCtD
Sumatriptan—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	4.61e-05	0.000193	CcSEcCtD
Sumatriptan—Dizziness—Etoposide—peripheral nervous system neoplasm	4.6e-05	0.000192	CcSEcCtD
Sumatriptan—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	4.59e-05	0.000192	CcSEcCtD
Sumatriptan—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	4.59e-05	0.000192	CcSEcCtD
Sumatriptan—HTR1F—Signaling Pathways—CD55—peripheral nervous system neoplasm	4.58e-05	0.00213	CbGpPWpGaD
Sumatriptan—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	4.58e-05	0.000191	CcSEcCtD
Sumatriptan—Chills—Doxorubicin—peripheral nervous system neoplasm	4.56e-05	0.000191	CcSEcCtD
Sumatriptan—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	4.54e-05	0.00019	CcSEcCtD
Sumatriptan—HTR1D—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.53e-05	0.0021	CbGpPWpGaD
Sumatriptan—Nausea—Cisplatin—peripheral nervous system neoplasm	4.51e-05	0.000189	CcSEcCtD
Sumatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	4.43e-05	0.00206	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.43e-05	0.00206	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	4.43e-05	0.00206	CbGpPWpGaD
Sumatriptan—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	4.43e-05	0.000185	CcSEcCtD
Sumatriptan—Vomiting—Etoposide—peripheral nervous system neoplasm	4.42e-05	0.000185	CcSEcCtD
Sumatriptan—Erythema—Doxorubicin—peripheral nervous system neoplasm	4.42e-05	0.000185	CcSEcCtD
Sumatriptan—Anaemia—Epirubicin—peripheral nervous system neoplasm	4.42e-05	0.000185	CcSEcCtD
Sumatriptan—Agitation—Epirubicin—peripheral nervous system neoplasm	4.39e-05	0.000184	CcSEcCtD
Sumatriptan—Rash—Etoposide—peripheral nervous system neoplasm	4.39e-05	0.000183	CcSEcCtD
Sumatriptan—Dermatitis—Etoposide—peripheral nervous system neoplasm	4.38e-05	0.000183	CcSEcCtD
Sumatriptan—Headache—Etoposide—peripheral nervous system neoplasm	4.36e-05	0.000182	CcSEcCtD
Sumatriptan—Flatulence—Doxorubicin—peripheral nervous system neoplasm	4.36e-05	0.000182	CcSEcCtD
Sumatriptan—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	4.33e-05	0.000181	CcSEcCtD
Sumatriptan—HTR1D—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.32e-05	0.002	CbGpPWpGaD
Sumatriptan—Malaise—Epirubicin—peripheral nervous system neoplasm	4.31e-05	0.00018	CcSEcCtD
Sumatriptan—Vertigo—Epirubicin—peripheral nervous system neoplasm	4.29e-05	0.00018	CcSEcCtD
Sumatriptan—Syncope—Epirubicin—peripheral nervous system neoplasm	4.28e-05	0.000179	CcSEcCtD
Sumatriptan—DRD2—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	4.28e-05	0.00199	CbGpPWpGaD
Sumatriptan—Back pain—Doxorubicin—peripheral nervous system neoplasm	4.28e-05	0.000179	CcSEcCtD
Sumatriptan—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	4.25e-05	0.000178	CcSEcCtD
Sumatriptan—HTR1A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	4.25e-05	0.00197	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	4.23e-05	0.00196	CbGpPWpGaD
Sumatriptan—Palpitations—Epirubicin—peripheral nervous system neoplasm	4.22e-05	0.000177	CcSEcCtD
Sumatriptan—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	4.2e-05	0.000176	CcSEcCtD
Sumatriptan—Cough—Epirubicin—peripheral nervous system neoplasm	4.17e-05	0.000174	CcSEcCtD
Sumatriptan—Convulsion—Epirubicin—peripheral nervous system neoplasm	4.14e-05	0.000173	CcSEcCtD
Sumatriptan—Nausea—Etoposide—peripheral nervous system neoplasm	4.13e-05	0.000173	CcSEcCtD
Sumatriptan—Hypertension—Epirubicin—peripheral nervous system neoplasm	4.12e-05	0.000173	CcSEcCtD
Sumatriptan—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	4.1e-05	0.000172	CcSEcCtD
Sumatriptan—SLCO1B1—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.09e-05	0.0019	CbGpPWpGaD
Sumatriptan—Anaemia—Doxorubicin—peripheral nervous system neoplasm	4.09e-05	0.000171	CcSEcCtD
Sumatriptan—Arthralgia—Epirubicin—peripheral nervous system neoplasm	4.07e-05	0.00017	CcSEcCtD
Sumatriptan—Chest pain—Epirubicin—peripheral nervous system neoplasm	4.07e-05	0.00017	CcSEcCtD
Sumatriptan—Myalgia—Epirubicin—peripheral nervous system neoplasm	4.07e-05	0.00017	CcSEcCtD
Sumatriptan—Agitation—Doxorubicin—peripheral nervous system neoplasm	4.06e-05	0.00017	CcSEcCtD
Sumatriptan—Anxiety—Epirubicin—peripheral nervous system neoplasm	4.05e-05	0.00017	CcSEcCtD
Sumatriptan—Discomfort—Epirubicin—peripheral nervous system neoplasm	4.02e-05	0.000168	CcSEcCtD
Sumatriptan—HTR1F—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	4e-05	0.00186	CbGpPWpGaD
Sumatriptan—Malaise—Doxorubicin—peripheral nervous system neoplasm	3.99e-05	0.000167	CcSEcCtD
Sumatriptan—Dry mouth—Epirubicin—peripheral nervous system neoplasm	3.98e-05	0.000166	CcSEcCtD
Sumatriptan—SLCO1A2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.98e-05	0.00185	CbGpPWpGaD
Sumatriptan—Vertigo—Doxorubicin—peripheral nervous system neoplasm	3.97e-05	0.000166	CcSEcCtD
Sumatriptan—MAOA—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	3.97e-05	0.00184	CbGpPWpGaD
Sumatriptan—Syncope—Doxorubicin—peripheral nervous system neoplasm	3.96e-05	0.000166	CcSEcCtD
Sumatriptan—HTR1D—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.96e-05	0.00184	CbGpPWpGaD
Sumatriptan—Confusional state—Epirubicin—peripheral nervous system neoplasm	3.93e-05	0.000164	CcSEcCtD
Sumatriptan—HTR1D—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.92e-05	0.00182	CbGpPWpGaD
Sumatriptan—Palpitations—Doxorubicin—peripheral nervous system neoplasm	3.91e-05	0.000163	CcSEcCtD
Sumatriptan—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	3.9e-05	0.000163	CcSEcCtD
Sumatriptan—Oedema—Epirubicin—peripheral nervous system neoplasm	3.9e-05	0.000163	CcSEcCtD
Sumatriptan—DRD2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	3.89e-05	0.00181	CbGpPWpGaD
Sumatriptan—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	3.88e-05	0.000162	CcSEcCtD
Sumatriptan—HTR1B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3.88e-05	0.0018	CbGpPWpGaD
Sumatriptan—Infection—Epirubicin—peripheral nervous system neoplasm	3.87e-05	0.000162	CcSEcCtD
Sumatriptan—HTR1A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	3.86e-05	0.00179	CbGpPWpGaD
Sumatriptan—Cough—Doxorubicin—peripheral nervous system neoplasm	3.86e-05	0.000161	CcSEcCtD
Sumatriptan—HTR1B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	3.84e-05	0.00178	CbGpPWpGaD
Sumatriptan—Shock—Epirubicin—peripheral nervous system neoplasm	3.84e-05	0.00016	CcSEcCtD
Sumatriptan—Convulsion—Doxorubicin—peripheral nervous system neoplasm	3.83e-05	0.00016	CcSEcCtD
Sumatriptan—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	3.82e-05	0.00016	CcSEcCtD
Sumatriptan—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	3.82e-05	0.00016	CcSEcCtD
Sumatriptan—Hypertension—Doxorubicin—peripheral nervous system neoplasm	3.82e-05	0.00016	CcSEcCtD
Sumatriptan—Tachycardia—Epirubicin—peripheral nervous system neoplasm	3.81e-05	0.000159	CcSEcCtD
Sumatriptan—ABCG2—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.79e-05	0.00176	CbGpPWpGaD
Sumatriptan—Skin disorder—Epirubicin—peripheral nervous system neoplasm	3.79e-05	0.000158	CcSEcCtD
Sumatriptan—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	3.77e-05	0.000158	CcSEcCtD
Sumatriptan—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000157	CcSEcCtD
Sumatriptan—Chest pain—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000157	CcSEcCtD
Sumatriptan—Myalgia—Doxorubicin—peripheral nervous system neoplasm	3.76e-05	0.000157	CcSEcCtD
Sumatriptan—Anxiety—Doxorubicin—peripheral nervous system neoplasm	3.75e-05	0.000157	CcSEcCtD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	3.74e-05	0.00174	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	3.73e-05	0.00173	CbGpPWpGaD
Sumatriptan—Discomfort—Doxorubicin—peripheral nervous system neoplasm	3.72e-05	0.000156	CcSEcCtD
Sumatriptan—HTR1A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	3.7e-05	0.00172	CbGpPWpGaD
Sumatriptan—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	3.68e-05	0.000154	CcSEcCtD
Sumatriptan—ABCG2—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	3.66e-05	0.0017	CbGpPWpGaD
Sumatriptan—Hypotension—Epirubicin—peripheral nervous system neoplasm	3.64e-05	0.000152	CcSEcCtD
Sumatriptan—Confusional state—Doxorubicin—peripheral nervous system neoplasm	3.64e-05	0.000152	CcSEcCtD
Sumatriptan—HTR1F—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	3.63e-05	0.00169	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—VIP—peripheral nervous system neoplasm	3.62e-05	0.00168	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.62e-05	0.00168	CbGpPWpGaD
Sumatriptan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	3.62e-05	0.00168	CbGpPWpGaD
Sumatriptan—Oedema—Doxorubicin—peripheral nervous system neoplasm	3.61e-05	0.000151	CcSEcCtD
Sumatriptan—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	3.61e-05	0.000151	CcSEcCtD
Sumatriptan—SLCO1A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	3.61e-05	0.00168	CbGpPWpGaD
Sumatriptan—Infection—Doxorubicin—peripheral nervous system neoplasm	3.58e-05	0.00015	CcSEcCtD
Sumatriptan—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	3.55e-05	0.000149	CcSEcCtD
Sumatriptan—Shock—Doxorubicin—peripheral nervous system neoplasm	3.55e-05	0.000148	CcSEcCtD
Sumatriptan—HTR1B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	3.54e-05	0.00164	CbGpPWpGaD
Sumatriptan—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	3.54e-05	0.000148	CcSEcCtD
Sumatriptan—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	3.53e-05	0.000148	CcSEcCtD
Sumatriptan—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	3.52e-05	0.000147	CcSEcCtD
Sumatriptan—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	3.5e-05	0.000147	CcSEcCtD
Sumatriptan—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	3.5e-05	0.000146	CcSEcCtD
Sumatriptan—HTR1F—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	3.5e-05	0.00163	CbGpPWpGaD
Sumatriptan—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	3.49e-05	0.000146	CcSEcCtD
Sumatriptan—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	3.48e-05	0.000145	CcSEcCtD
Sumatriptan—Somnolence—Epirubicin—peripheral nervous system neoplasm	3.47e-05	0.000145	CcSEcCtD
Sumatriptan—SLCO1A2—Metabolism—GNS—peripheral nervous system neoplasm	3.46e-05	0.00161	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	3.41e-05	0.00158	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	3.4e-05	0.00158	CbGpPWpGaD
Sumatriptan—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	3.39e-05	0.000142	CcSEcCtD
Sumatriptan—DRD2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	3.39e-05	0.00157	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.38e-05	0.00157	CbGpPWpGaD
Sumatriptan—HTR1A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	3.37e-05	0.00157	CbGpPWpGaD
Sumatriptan—Hypotension—Doxorubicin—peripheral nervous system neoplasm	3.37e-05	0.000141	CcSEcCtD
Sumatriptan—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	3.37e-05	0.000141	CcSEcCtD
Sumatriptan—Fatigue—Epirubicin—peripheral nervous system neoplasm	3.36e-05	0.000141	CcSEcCtD
Sumatriptan—HTR1F—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	3.34e-05	0.00155	CbGpPWpGaD
Sumatriptan—Pain—Epirubicin—peripheral nervous system neoplasm	3.33e-05	0.000139	CcSEcCtD
Sumatriptan—Constipation—Epirubicin—peripheral nervous system neoplasm	3.33e-05	0.000139	CcSEcCtD
Sumatriptan—SLCO1A2—Metabolism—NME1—peripheral nervous system neoplasm	3.32e-05	0.00154	CbGpPWpGaD
Sumatriptan—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	3.29e-05	0.000137	CcSEcCtD
Sumatriptan—DRD2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	3.25e-05	0.00151	CbGpPWpGaD
Sumatriptan—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	3.24e-05	0.000135	CcSEcCtD
Sumatriptan—HTR1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.22e-05	0.0015	CbGpPWpGaD
Sumatriptan—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	3.22e-05	0.000135	CcSEcCtD
Sumatriptan—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	3.21e-05	0.000134	CcSEcCtD
Sumatriptan—Somnolence—Doxorubicin—peripheral nervous system neoplasm	3.21e-05	0.000134	CcSEcCtD
Sumatriptan—MAOA—Metabolism—GNS—peripheral nervous system neoplasm	3.21e-05	0.00149	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—COX2—peripheral nervous system neoplasm	3.19e-05	0.00148	CbGpPWpGaD
Sumatriptan—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	3.19e-05	0.000133	CcSEcCtD
Sumatriptan—HTR1F—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	3.18e-05	0.00148	CbGpPWpGaD
Sumatriptan—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	3.16e-05	0.00147	CbGpPWpGaD
Sumatriptan—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	3.14e-05	0.000131	CcSEcCtD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	3.12e-05	0.00145	CbGpPWpGaD
Sumatriptan—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.00013	CcSEcCtD
Sumatriptan—Fatigue—Doxorubicin—peripheral nervous system neoplasm	3.11e-05	0.00013	CcSEcCtD
Sumatriptan—Urticaria—Epirubicin—peripheral nervous system neoplasm	3.1e-05	0.00013	CcSEcCtD
Sumatriptan—Pain—Doxorubicin—peripheral nervous system neoplasm	3.08e-05	0.000129	CcSEcCtD
Sumatriptan—Constipation—Doxorubicin—peripheral nervous system neoplasm	3.08e-05	0.000129	CcSEcCtD
Sumatriptan—SLCO1B1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	3.08e-05	0.00143	CbGpPWpGaD
Sumatriptan—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	3.08e-05	0.000129	CcSEcCtD
Sumatriptan—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	3.08e-05	0.000129	CcSEcCtD
Sumatriptan—MAOA—Metabolism—NME1—peripheral nervous system neoplasm	3.07e-05	0.00143	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NTS—peripheral nervous system neoplasm	3.05e-05	0.00142	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.03e-05	0.00141	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.99e-05	0.00139	CbGpPWpGaD
Sumatriptan—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	2.97e-05	0.000124	CcSEcCtD
Sumatriptan—DRD2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	2.97e-05	0.00138	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—GNS—peripheral nervous system neoplasm	2.96e-05	0.00137	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—COX2—peripheral nervous system neoplasm	2.96e-05	0.00137	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	2.95e-05	0.00137	CbGpPWpGaD
Sumatriptan—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	2.95e-05	0.000123	CcSEcCtD
Sumatriptan—HTR1D—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.93e-05	0.00136	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	2.92e-05	0.00136	CbGpPWpGaD
Sumatriptan—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	2.92e-05	0.00136	CbGpPWpGaD
Sumatriptan—SLCO1A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.9e-05	0.00135	CbGpPWpGaD
Sumatriptan—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	2.87e-05	0.00012	CcSEcCtD
Sumatriptan—HTR1B—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.87e-05	0.00133	CbGpPWpGaD
Sumatriptan—Urticaria—Doxorubicin—peripheral nervous system neoplasm	2.87e-05	0.00012	CcSEcCtD
Sumatriptan—ABCG2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	2.86e-05	0.00133	CbGpPWpGaD
Sumatriptan—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	2.85e-05	0.000119	CcSEcCtD
Sumatriptan—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	2.85e-05	0.000119	CcSEcCtD
Sumatriptan—SLCO1A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.85e-05	0.00132	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—NME1—peripheral nervous system neoplasm	2.84e-05	0.00132	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	2.83e-05	0.00131	CbGpPWpGaD
Sumatriptan—Asthenia—Epirubicin—peripheral nervous system neoplasm	2.8e-05	0.000117	CcSEcCtD
Sumatriptan—Pruritus—Epirubicin—peripheral nervous system neoplasm	2.76e-05	0.000115	CcSEcCtD
Sumatriptan—ABCG2—Metabolism—GNS—peripheral nervous system neoplasm	2.74e-05	0.00127	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—COX2—peripheral nervous system neoplasm	2.73e-05	0.00127	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.7e-05	0.00125	CbGpPWpGaD
Sumatriptan—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	2.67e-05	0.000112	CcSEcCtD
Sumatriptan—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	2.66e-05	0.000111	CcSEcCtD
Sumatriptan—ABCG2—Metabolism—NME1—peripheral nervous system neoplasm	2.63e-05	0.00122	CbGpPWpGaD
Sumatriptan—DRD2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	2.59e-05	0.0012	CbGpPWpGaD
Sumatriptan—Asthenia—Doxorubicin—peripheral nervous system neoplasm	2.59e-05	0.000108	CcSEcCtD
Sumatriptan—Dizziness—Epirubicin—peripheral nervous system neoplasm	2.58e-05	0.000108	CcSEcCtD
Sumatriptan—DRD2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	2.57e-05	0.00119	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.56e-05	0.00119	CbGpPWpGaD
Sumatriptan—Pruritus—Doxorubicin—peripheral nervous system neoplasm	2.55e-05	0.000107	CcSEcCtD
Sumatriptan—ABCG2—Metabolism—COX2—peripheral nervous system neoplasm	2.53e-05	0.00117	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	2.51e-05	0.00117	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	2.51e-05	0.00116	CbGpPWpGaD
Sumatriptan—SLCO1B1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.48e-05	0.00115	CbGpPWpGaD
Sumatriptan—Vomiting—Epirubicin—peripheral nervous system neoplasm	2.48e-05	0.000104	CcSEcCtD
Sumatriptan—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	2.47e-05	0.000103	CcSEcCtD
Sumatriptan—Rash—Epirubicin—peripheral nervous system neoplasm	2.46e-05	0.000103	CcSEcCtD
Sumatriptan—Dermatitis—Epirubicin—peripheral nervous system neoplasm	2.46e-05	0.000103	CcSEcCtD
Sumatriptan—Headache—Epirubicin—peripheral nervous system neoplasm	2.44e-05	0.000102	CcSEcCtD
Sumatriptan—SLCO1B1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.44e-05	0.00113	CbGpPWpGaD
Sumatriptan—Dizziness—Doxorubicin—peripheral nervous system neoplasm	2.39e-05	9.98e-05	CcSEcCtD
Sumatriptan—DRD2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.37e-05	0.0011	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.32e-05	0.00108	CbGpPWpGaD
Sumatriptan—Nausea—Epirubicin—peripheral nervous system neoplasm	2.32e-05	9.69e-05	CcSEcCtD
Sumatriptan—HTR1D—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.32e-05	0.00108	CbGpPWpGaD
Sumatriptan—ABCG2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.3e-05	0.00107	CbGpPWpGaD
Sumatriptan—Vomiting—Doxorubicin—peripheral nervous system neoplasm	2.29e-05	9.59e-05	CcSEcCtD
Sumatriptan—HTR1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.28e-05	0.00106	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	2.28e-05	0.00106	CbGpPWpGaD
Sumatriptan—Rash—Doxorubicin—peripheral nervous system neoplasm	2.27e-05	9.51e-05	CcSEcCtD
Sumatriptan—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	2.27e-05	9.51e-05	CcSEcCtD
Sumatriptan—HTR1B—Signaling Pathways—VIP—peripheral nervous system neoplasm	2.27e-05	0.00105	CbGpPWpGaD
Sumatriptan—Headache—Doxorubicin—peripheral nervous system neoplasm	2.26e-05	9.45e-05	CcSEcCtD
Sumatriptan—ABCG2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.25e-05	0.00105	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.24e-05	0.00104	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	2.21e-05	0.00103	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	2.19e-05	0.00102	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.18e-05	0.00101	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.15e-05	0.000997	CbGpPWpGaD
Sumatriptan—Nausea—Doxorubicin—peripheral nervous system neoplasm	2.14e-05	8.96e-05	CcSEcCtD
Sumatriptan—HTR1D—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.14e-05	0.000992	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—ENO2—peripheral nervous system neoplasm	2.1e-05	0.000974	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	2.09e-05	0.000972	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.05e-05	0.000951	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.05e-05	0.00095	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	2.03e-05	0.000944	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NTS—peripheral nervous system neoplasm	2e-05	0.000929	CbGpPWpGaD
Sumatriptan—MAOA—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2e-05	0.000927	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.99e-05	0.000924	CbGpPWpGaD
Sumatriptan—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	1.98e-05	0.000918	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—ENO2—peripheral nervous system neoplasm	1.94e-05	0.000902	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CD55—peripheral nervous system neoplasm	1.92e-05	0.000891	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.91e-05	0.000886	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.88e-05	0.000872	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—ENO2—peripheral nervous system neoplasm	1.79e-05	0.000833	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—BCHE—peripheral nervous system neoplasm	1.77e-05	0.000823	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.73e-05	0.000805	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.73e-05	0.000802	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	1.72e-05	0.000798	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.69e-05	0.000785	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.68e-05	0.000778	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.67e-05	0.000775	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—TH—peripheral nervous system neoplasm	1.67e-05	0.000773	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—ENO2—peripheral nervous system neoplasm	1.66e-05	0.000771	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—BCHE—peripheral nervous system neoplasm	1.64e-05	0.000762	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.6e-05	0.000745	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.59e-05	0.00074	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.57e-05	0.00073	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.57e-05	0.000727	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.56e-05	0.000725	CbGpPWpGaD
Sumatriptan—DRD2—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	1.55e-05	0.00072	CbGpPWpGaD
Sumatriptan—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.54e-05	0.000717	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—TH—peripheral nervous system neoplasm	1.54e-05	0.000717	CbGpPWpGaD
Sumatriptan—MAOA—Neuronal System—HRAS—peripheral nervous system neoplasm	1.53e-05	0.00071	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.52e-05	0.000707	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.52e-05	0.000704	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.52e-05	0.000704	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—BCHE—peripheral nervous system neoplasm	1.51e-05	0.000703	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	1.48e-05	0.000688	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.47e-05	0.000681	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.44e-05	0.000671	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—TH—peripheral nervous system neoplasm	1.42e-05	0.000661	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.42e-05	0.00066	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.41e-05	0.000656	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—BCHE—peripheral nervous system neoplasm	1.4e-05	0.000651	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.4e-05	0.00065	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.38e-05	0.000642	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.37e-05	0.000638	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.37e-05	0.000635	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.36e-05	0.000631	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.34e-05	0.000624	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.34e-05	0.000621	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.33e-05	0.00062	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.33e-05	0.000618	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	1.33e-05	0.000617	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—TH—peripheral nervous system neoplasm	1.32e-05	0.000612	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.31e-05	0.000608	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.3e-05	0.000606	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	1.28e-05	0.000595	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—GNAS—peripheral nervous system neoplasm	1.26e-05	0.000585	CbGpPWpGaD
Sumatriptan—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.24e-05	0.000577	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—ABCB1—peripheral nervous system neoplasm	1.24e-05	0.000574	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.22e-05	0.000566	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.2e-05	0.000558	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.2e-05	0.000556	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	1.18e-05	0.000546	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—GNAS—peripheral nervous system neoplasm	1.16e-05	0.00054	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.14e-05	0.00053	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—GNAS—peripheral nervous system neoplasm	1.08e-05	0.0005	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.06e-05	0.000491	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.05e-05	0.000489	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.05e-05	0.000488	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.03e-05	0.000479	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.02e-05	0.000476	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1e-05	0.000465	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	9.76e-06	0.000453	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	9.71e-06	0.000451	CbGpPWpGaD
Sumatriptan—HTR1F—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	9.44e-06	0.000439	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—CASP3—peripheral nervous system neoplasm	9.36e-06	0.000435	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	9.25e-06	0.00043	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	8.99e-06	0.000418	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	8.97e-06	0.000417	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	8.95e-06	0.000416	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	8.58e-06	0.000398	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	8.57e-06	0.000398	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.49e-06	0.000394	CbGpPWpGaD
Sumatriptan—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	8.45e-06	0.000392	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.34e-06	0.000387	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	8.31e-06	0.000386	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	8.17e-06	0.000379	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	7.86e-06	0.000365	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—NRAS—peripheral nervous system neoplasm	7.84e-06	0.000364	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	7.58e-06	0.000352	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—MYC—peripheral nervous system neoplasm	7.31e-06	0.000339	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.23e-06	0.000336	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	7.13e-06	0.000331	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.59e-06	0.000306	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	6.45e-06	0.0003	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.33e-06	0.000294	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.22e-06	0.000289	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.21e-06	0.000289	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	6.08e-06	0.000282	CbGpPWpGaD
Sumatriptan—HTR1D—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	6.04e-06	0.000281	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—TP53—peripheral nervous system neoplasm	6e-06	0.000279	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.98e-06	0.000278	CbGpPWpGaD
Sumatriptan—HTR1B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	5.91e-06	0.000275	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	5.86e-06	0.000272	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	5.82e-06	0.00027	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—HRAS—peripheral nervous system neoplasm	5.74e-06	0.000267	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	5.56e-06	0.000258	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.48e-06	0.000255	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.46e-06	0.000254	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	5.37e-06	0.000249	CbGpPWpGaD
Sumatriptan—HTR1F—Signaling Pathways—AKT1—peripheral nervous system neoplasm	5.07e-06	0.000235	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—NRAS—peripheral nervous system neoplasm	5.02e-06	0.000233	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.92e-06	0.000228	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	4.91e-06	0.000228	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.67e-06	0.000217	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.63e-06	0.000215	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—MYC—peripheral nervous system neoplasm	4.57e-06	0.000212	CbGpPWpGaD
Sumatriptan—HTR1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.5e-06	0.000209	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.46e-06	0.000207	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.32e-06	0.000201	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.09e-06	0.00019	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.07e-06	0.000189	CbGpPWpGaD
Sumatriptan—DRD2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	3.96e-06	0.000184	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.92e-06	0.000182	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.84e-06	0.000178	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—TP53—peripheral nervous system neoplasm	3.76e-06	0.000174	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.74e-06	0.000174	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.67e-06	0.00017	CbGpPWpGaD
Sumatriptan—SLCO1A2—Metabolism—AKT1—peripheral nervous system neoplasm	3.67e-06	0.00017	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	3.59e-06	0.000167	CbGpPWpGaD
Sumatriptan—DRD2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	3.59e-06	0.000167	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.48e-06	0.000162	CbGpPWpGaD
Sumatriptan—MAOA—Metabolism—AKT1—peripheral nervous system neoplasm	3.4e-06	0.000158	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.28e-06	0.000153	CbGpPWpGaD
Sumatriptan—HTR1D—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.24e-06	0.00015	CbGpPWpGaD
Sumatriptan—HTR1B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	3.17e-06	0.000147	CbGpPWpGaD
Sumatriptan—SLCO1B1—Metabolism—AKT1—peripheral nervous system neoplasm	3.14e-06	0.000146	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.06e-06	0.000142	CbGpPWpGaD
Sumatriptan—ABCG2—Metabolism—AKT1—peripheral nervous system neoplasm	2.91e-06	0.000135	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.86e-06	0.000133	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.74e-06	0.000127	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.51e-06	0.000117	CbGpPWpGaD
Sumatriptan—HTR1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.42e-06	0.000112	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.4e-06	0.000112	CbGpPWpGaD
Sumatriptan—DRD2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.12e-06	9.86e-05	CbGpPWpGaD
Sumatriptan—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.57e-06	7.3e-05	CbGpPWpGaD
